Nucleus RadioPharma’s Post

Advancements in personalized medicine & targeted therapies have revolutionized cancer treatment, offering higher efficacy and fewer side effects. Click @ https://lnkd.in/dVVZHSQT to gather the latest insights into the U.S. Pharmaceutical Market. FDA #gvr #healthcare #healthcareinnovation #healthcareindustry #personalizedmedicine #cancertreatment #pharmaceuticalindustry #pharmaceutical #industryupdates

Navigating the Evolving Landscape of Prefilled Syringe Packaging in the Biologics Market: https://lnkd.in/gMiBHCs6 The PFS Advantage. Prefilled syringes (PFS) are reshaping drug delivery in biologics, catering to patient needs and streamlining administration. Empowering self-administration and enhancing safety, PFS represents a pivotal advancement. Yet, navigating this landscape demands ongoing innovation and strategic partnerships. Together, we're charting a course towards accessible, patient-centric care.

In a recent interview with European Pharmaceutical Manufacturer, our very own Eric Kaneps discussed how innovation is impacting the nasal spray market as well as challenges nasal spray developers are currently facing. To read the full interview, click the link below! #CDMO #pharma

Medincell announces a strategic partnership with AbbVie to develop up to six innovative therapies leveraging Medincell’s long-acting injectable platform. While Medincell will handle formulation, preclinical studies, and CMC work, AbbVie will lead clinical trials, regulatory approvals, manufacturing, and commercialization. This collaboration includes an initial $35 million payment, with potential milestone payments and royalties of up to $1.9 billion. Additionally, Medincell partners with Teva for the commercialization of UZEDY® and mdc-TJK, utilizing its BEPO® long-acting injection technology. This collaboration may result in milestone payments and royalties totaling up to $222 million. BEPO® technology offers precise drug delivery over extended periods, enhancing treatment compliance, efficacy, and accessibility. Medincell, a biopharmaceutical company, focuses on developing long-acting injectable drugs to improve patient compliance and drug effectiveness. The company's FDA-approved UZEDY® for schizophrenia, based on the BEPO® technology, is currently marketed by Teva. Learn more about Medincell's groundbreaking progress and collaborations with AbbVie and Teva here: https://lnkd.in/d5D7UuBs Pauline Marces E. Louise Lagerqvist PhD, MBA Sebastien Enault

Regulatory approval marks a critical hurdle in #biopharmaceutical development, and with an influx of antibody-based therapeutics facing fierce competition, streamlining the path to IND submission is paramount. Critical to reducing these timelines is having an integrated approach to development, coordinating overlapping activities to obtain IND enabling data in as short a timeframe as possible. A robust CLD strategy prioritizes early developability and manufacturability assessments of both cell lines and molecules to mitigate risks and delays. In this webinar, Abzena shares valuable insights for optimizing CLD practices and how to accelerate the journey toward first-in-human clinical trials and proof-of-concept studies.

Medincell and AbbVie 𝗵𝗮𝘃𝗲 𝗮𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗱 𝗮 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘁𝗼 𝗰𝗼-𝗱𝗲𝘃𝗲𝗹𝗼𝗽 𝗮𝗻𝗱 𝗰𝗼𝗺𝗺𝗲𝗿𝗰𝗶𝗮𝗹𝗶𝘇𝗲 𝘂𝗽 𝘁𝗼 𝘀𝗶𝘅 𝗶𝗻𝗷𝗲𝗰𝘁𝗮𝗯𝗹𝗲 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀, 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗱𝗲𝗮𝗹 𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝘁 𝗻𝗲𝗮𝗿𝗹𝘆 $𝟮 𝗯𝗶𝗹𝗹𝗶𝗼𝗻. Medincell stands to earn up to $1.9 billion in development and commercial milestones, with $35 million upfront and royalties on sales. Medincell will handle formulation and pre-clinical trials, while AbbVie will finance and conduct clinical development, as well as manage regulatory approval, manufacturing, and commercialization. These therapies will utilize Medincell's long-acting injectable technology platform, with Medincell having received its first U.S. regulatory approval for such a product in April 2023. #Biopharma #Pharmaceuticals #DrugDevelopment #HealthcareInnovation #MedTech #biotech https://lnkd.in/eMdaYDvU

WuXi Biologics published a research paper titled "Advancing injection force modeling and viscosity-dependent injectability evaluation for prefilled syringes" in the European Journal of Pharmaceutics and Biopharmaceutics (by Wu L, Li H, Wang Y, Li C, Zhao Z, Zhuang G, Chen Q, Zhou W, and Guo J). The study explores cutting-edge advancements in injection force modeling and examines the crucial role of viscosity in injectability. Our findings promise to revolutionize the development of prefilled syringe drug products, paving the way for enhanced drug delivery systems and improved patient outcomes. Don't miss this groundbreaking article. https://lnkd.in/eGYZiaHp #CRDMO #prefilledsyringe

FDA granted ATEV of Humacyte a special advanced-therapy designation on Monday. Find out more. https://lnkd.in/dN-r94hs #humacyte #investing #fda #regulator #stockmarketnews #unitedstates #biotech #healthcare #pharmaceuticals #businessnews #heartdisease #foodanddrugadministration

This study explores the strategic significance of engaging Key Opinion Leaders (KOLs) within the pharmaceutical sector. It demonstrates how a prominent cardiovascular therapeutics company utilized KOLs to solidify its market position for its new medication. Read Now: https://lnkd.in/dziEhgZA #PharmaScroll #healthcare #pharmaceutical #casestudy #keyopinionleaders #research #drugdevelopment #blogpost #pharmaresearch

Exciting news for the pharmaceutical industry! Learn about the latest developments in the pipeline for treating bronchiectasis. #PharmaNews #BronchiectasisResearch